Organon & Co. Hits New 52-Week High at USD 13.77

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.77 on August 26, 2026. This achievement marks a notable rebound from its 52-week low of USD 5.69, reflecting a substantial increase in its stock price over the past year. Despite the recent uptick, Organon & Co. has experienced a 1-year performance decline of 33.51%, contrasting sharply with the S&P 500's gain of 18.71% during the same period. The company's market capitalization stands at USD 1,520 million, and it boasts a price-to-earnings (P/E) ratio of 3.00, indicating a potentially attractive valuation relative to its earnings. Additionally, Organon & Co. offers a dividend yield of 1.02% and maintains a strong return on equity of 69.90%. With a debt-to-equity ratio of 10.78 and a price-to-book ratio of 2.02, the company appears to be managing its financial structure effectively. This recent price movement highlights the stock's current position in the market and its performance metrics.